Analysts have been eager to weigh in on the Healthcare sector with new ratings on Catalyst Biosciences Inc (NASDAQ:CBIO) and Epizyme (NASDAQ:EPZM).
Catalyst Biosciences Inc (CBIO)
In a report released today, Gbola Amusa from Chardan Capital reiterated a Buy rating on Catalyst Biosciences Inc, with a price target of $35. The company’s shares closed yesterday at $10.04.
According to TipRanks.com, Amusa is a 5-star analyst with an average return of 25.8% and a 55.0% success rate. Amusa covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Nightstar Therapeutics Limited, and Applied Genetic Technologies.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Catalyst Biosciences Inc with a $23.75 average price target.
See today’s analyst top recommended stocks >>
Epizyme (EPZM)
In a report released today, David Lebovitz from Morgan Stanley maintained a Hold rating on Epizyme, with a price target of $12. The company’s shares closed yesterday at $10, close to its 52-week low of $8.61.
According to TipRanks.com, Lebovitz is a 3-star analyst with an average return of 22.8% and a 50.0% success rate. Lebovitz covers the Healthcare sector, focusing on stocks such as Rhythm Pharmaceuticals Inc, Akebia Therapeutics, and Alnylam Pharma.
Currently, the analyst consensus on Epizyme is a Strong Buy with an average price target of $25.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
